Top

Published in:

Open Access 01-09-2018 | Clinical Study

Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy

Authors: Pim B. van der Meer, Esther J. J. Habets, Ruud G. Wiggenraad, Antoinette Verbeek-de Kanter, Geert J. Lycklama à Nijeholt, Hanneke Zwinkels, Martin Klein, Linda Dirven, Martin J. B. Taphoorn

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Background

Recently, it has been shown that at group level, patients with limited brain metastases treated with stereotactic radiotherapy (SRT) maintain their pre-treatment levels of neurocognitive functioning (NCF) and health-related quality of life (HRQoL). The aim of this study was to evaluate NCF and HRQoL changes over time at the individual patient level.

Methods

NCF (seven domains assessed with a standardized test battery) and HRQoL (eight predetermined scales assessed with the EORTC QLQ-C30 and BN20 questionnaires) were measured prior to SRT and at 3 and/or 6 months follow-up. Changes in NCF and HRQoL were evaluated at (1) a domain/scale level and (2) patient level.

Results

A total of 55 patients were examined, of which the majority showed stable NCF 3 months after SRT, on both the domain level (78–100% of patients) and patient level (67% of patients). This was different for HRQoL, where deterioration in the different scales was observed in 12–61% of patients, stable scores in 20–71%, and improvement in 16–40%, 3 months after SRT. At patient level, most patients (64%) showed both improvement and deterioration in different HRQoL scales. Results were similar between 3 and 6 months after SRT.

Conclusion

In line with results at group level, most brain oligometastases patients with ≥ 6 months follow-up and treated with SRT maintained their pre-treatment level of NCF during this period. By contrast, changes in HRQoL scores differed considerably at domain and patient level, despite stable HRQoL scores at group level.

Available only for authorised users

Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705. https://doi.org/10.1002/cncr.10541 CrossRefPubMed

Barnholtz-Sloan JS, Yu CH, Sloan AE, Vengoechea J, Wang MH, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M, Kattan MW (2012) A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 14(7):910–918. https://doi.org/10.1093/neuonc/nos087 CrossRefPubMedPubMedCentral

Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14(1):48–54. https://doi.org/10.1007/s11912-011-0203-y CrossRefPubMed

Soffietti R, Ruda R, Trevisan E (2008) Brain metastases: current management and new developments. Curr Opin Oncol 20(6):676–684. https://doi.org/10.1097/CCO.0b013e32831186fe CrossRefPubMed

Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY (2016) Updates in the management of brain metastases. Neuro Oncol 18(8):1043–1065. https://doi.org/10.1093/neuonc/now127 CrossRefPubMedPubMedCentral

Kamar FG, Posner JB (2010) Brain metastases. Semin Neurol 30(3):217–235. https://doi.org/10.1055/s-0030-1255225 CrossRefPubMed

Day J, Gillespie DC, Rooney AG, Bulbeck HJ, Zienius K, Boele F, Grant R (2016) Neurocognitive deficits and neurocognitive rehabilitation in adult brain tumors. Curr Treat Options Neurol. https://doi.org/10.1007/s11940-016-0406-5 PubMedCrossRef

Kaal ECA, Niël CGJH., Vecht CJ (2005) Therapeutic management of brain metastasis. Lancet Neurol 4(5):289–298. https://doi.org/10.1016/s1474-4422(05)70072-7 CrossRefPubMed

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044. https://doi.org/10.1016/s1470-2045(09)70263-3 CrossRefPubMed

10.

Pectasides D, Pectasides M, Economopoulos T (2006) Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist 11(3):252–260. https://doi.org/10.1634/theoncologist.11-3-252 CrossRefPubMed

11.

Dirven L, Reijneveld JC, Taphoorn MJB (2014) Health-related quality of life or quantity of life: a difficult trade-off in primary brain tumors? Semin Oncol 41(4):541–552. https://doi.org/10.1053/j.seminoncol.2014.06.002 CrossRefPubMed

12.

Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS (2014) Monitoring and optimising cognitive function in cancer patients: present knowledge and future directions. EJC Suppl 12(1):29–40. https://doi.org/10.1016/j.ejcsup.2014.03.003 CrossRefPubMedPubMedCentral

13.

Muller-Riemenschneider F, Bockelbrink A, Ernst I, Schwarzbach C, Vauth C, von der Schulenburg JM, Willich SN (2009) Stereotactic radiosurgery for the treatment of brain metastases. Radiother Oncol 91(1):67–74. https://doi.org/10.1016/j.radonc.2008.12.001 CrossRefPubMed

14.

Halasz LM, Rockhill JK (2013) Stereotactic radiosurgery and stereotactic radiotherapy for brain metastases. Surg Neurol Int 4(Suppl 4):S185–S191. https://doi.org/10.4103/2152-7806.111295 PubMedPubMedCentralCrossRef

15.

Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, Shaw P, Beyene J, Chang EL (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91(4):710–717. https://doi.org/10.1016/j.ijrobp.2014.10.024 CrossRefPubMed

16.

Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75(1):5–14. https://doi.org/10.1007/s11060-004-8093-6 CrossRefPubMed

17.

Soliman H, Das S, Larson DA, Sahgal A (2016) Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget 7(11):12318–12330. https://doi.org/10.18632/oncotarget.7131 CrossRefPubMedPubMedCentral

18.

Scoccianti S, Ricardi U (2012) Treatment of brain metastases: review of phase III randomized controlled trials. Radiother Oncol 102(2):168–179. https://doi.org/10.1016/j.radonc.2011.08.041 CrossRefPubMed

19.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases—a randomized controlled trial. JAMA 295(21):2483–2491. https://doi.org/10.1001/jama.295.21.2483 CrossRefPubMed

20.

Regine WF, Huhn JL, Patchell RA, St Clair WH, Strottmann J, Meigooni A, Sanders M, Young AB (2002) Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 52(2):333–338. https://doi.org/10.1016/s0360-3016(01)02645-1 CrossRefPubMed

21.

Habets EJJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, Nijeholt G, Zwinkels H, Klein M, Taphoorn MJB (2016) Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro Oncol 18(3):435–444. https://doi.org/10.1093/neuonc/nov186 CrossRefPubMed

22.

Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment. Oxford University Press, New York

23.

Tucha O, Smely C, Preier M, Lange KW (2000) Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 47(2):324–333. https://doi.org/10.1097/00006123-200008000-00011 CrossRefPubMed

24.

Saan RJ, Deelman BG (1986) De 15-woordentest A en B (een voorlopige handleiding) [The 15 words test A and B (a preliminary manual)]. Afdeling Neuropsychologie, AZG, Groningen

25.

Uterwijk JMR (2000) WAIS-III Nederlandstalige bewerking. Technische handleiding. David Wechsler [WAIS-III Dutch revision. Technical manual. David Wechsler] Wechsler Adult Intelligence Scale III [Dutch revision. Technical manual]. Swets Test Publishers, Lisse

26.

Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J (2006) The concept shifting test: adult normative data. Psychol Assess 18(4):424. https://doi.org/10.1037/1040-3590.18.4.424 CrossRefPubMed

27.

Krabbendam L, Kalff AC (1998) The behavioural assessment of the dysexecutive syndrome: Dutch version. Swets and Zeitlinger, Lisse

28.

Meyers CA, Cantor SB (2003) Neuropsychological assessment and treatment of patients with malignant brain tumors. In: Prigatano GP, Pliskin NH (eds) Clinical neuropsychology and cost outcome research: a beginning. Psychology Press, New York, pp 159–173

29.

Osterreith PA (1944) Le test de copie d’une figure complexe [A test regarding a complex figure]. Arch Psychol 30:206–356

30.

Jolles J, van Boxtel MP, Ponds RW, Metsemakers JF, Houx PJ (1998) [The Maastricht aging study (MAAS). The longitudinal perspective of cognitive aging]. Tijdschr Gerontol Geriatr 29(3):120–129PubMed

31.

De Bie SE (1987) Standaardvragen 1987: Voorstellen voor uniformering van vraagstellingen naar achtergrondkenmerken en interviews [Standard questions 1987: proposal for uniformisation of questions regarding background variables and interviews]. Leiden University Press, Leiden

32.

Van der Elst W (2006) The neuropsychometrics of aging: normative studies in the Maastricht Aging Study. University of Maastricht, Maastricht

33.

Fastenau PS, Denburg NL, Hufford BJ (1999) Adult norms for the Rey-Osterrieth complex figure test and for supplemental recognition and matching trials from the extended complex figure test. Clin Neuropsychol 13(1):30–47. https://doi.org/10.1076/clin.13.1.30.1976 CrossRefPubMed

34.

Kessels RP, van den Berg E, Ruis C, Brands AM (2008) The backward span of the Corsi Block-Tapping Task and its association with the WAIS-III Digit Span. Assessment 15(4):426–434. https://doi.org/10.1177/1073191108315611 CrossRefPubMed

35.

Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WKA, Brada M, Newlands E (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1):139–150. https://doi.org/10.1007/bf00435979 CrossRefPubMed

36.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Dehaes J, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365 CrossRefPubMed

37.

Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Mueller RP, Tridello G, Collette L, Bottomley A (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65–72. https://doi.org/10.1200/jco.2011.41.0639 CrossRefPubMed

38.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144CrossRefPubMed

39.

van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM, Taphoorn MJ, Aaronson NK (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47(5):667–675. https://doi.org/10.1016/j.ejca.2010.11.004 CrossRefPubMed

40.

Chang EL, Wefel JS, Maor MH, Hassenbusch SJ III, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA (2007) A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60(2):277–283. https://doi.org/10.1227/01.neu.0000249272.64439.b1 CrossRefPubMed

41.

Minniti G, Esposito V, Clarke E, Scaringi C, Bozzao A, Lanzetta G, De Sanctis V, Valeriani M, Osti M, Enrici RM (2013) Stereotactic radiosurgery in elderly patients with brain metastases. J Neurooncol 111(3):319–325. https://doi.org/10.1007/s11060-012-1016-z CrossRefPubMed

42.

Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157–165. https://doi.org/10.1200/jco.2004.05.128 CrossRefPubMed

43.

Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, Delis DC (2009) Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry 17(5):368–375. https://doi.org/10.1097/JGP.0b013e31819431d5 CrossRefPubMedPubMedCentral

44.

Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4):401–409. https://doi.org/10.1001/jama.2016.9839 CrossRefPubMedPubMedCentral

45.

Caissie A, Nguyen J, Chen E, Zhang L, Sahgal A, Clemons M, Kerba M, Arnalot PF, Danjoux C, Tsao M, Barnes E, Holden L, Danielson B, Chow E (2012) Quality of life in patients with brain metastases using the EORTC QLQ-BN20 + 2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys 83(4):1238–1245. https://doi.org/10.1016/j.ijrobp.2011.09.025 CrossRefPubMed

46.

Steinmann D, Paelecke-Habermann Y, Geinitz H, Aschoff R, Bayerl A, Bölling T, Bosch E, Bruns F, Eichenseder-Seiss U, Gerstein J, Gharbi N, Hagg J, Hipp M, Kleff I, Müller A, Schäfer C, Schleicher U, Sehlen S, Theodorou M, Wypior H-J, Zehentmayr F, van Oorschot B, Vordermark D (2012) Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer 12(1):283. https://doi.org/10.1186/1471-2407-12-283 CrossRefPubMedPubMedCentral

47.

Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis WW, Arora NK, Haffer SC, Clauser SB (2009) Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst 101(12):860–868. https://doi.org/10.1093/jnci/djp123 CrossRefPubMedPubMedCentral

48.

Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273(1):59–65CrossRefPubMed

49.

Caissie A, Culleton S, Nguyen J, Zhang L, Zeng L, Holden L, Dennis K, Chan E, Jon F, Tsao M, Danjoux C, Sahgal A, Barnes E, Koo K, Chow E (2011) What QLQ-C15-PAL symptoms matter most for overall quality of life in patients with advanced cancer? World J Oncol 2(4):166–174PubMedPubMedCentral

Title: Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy
Authors: Pim B. van der Meer
Esther J. J. Habets
Ruud G. Wiggenraad
Antoinette Verbeek-de Kanter
Geert J. Lycklama à Nijeholt
Hanneke Zwinkels
Martin Klein
Linda Dirven
Martin J. B. Taphoorn
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2868-7

At a glance: The STEP trials

Springer Medicine

Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?

Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma

Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design

Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals

18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study

Management of glioblastoma at safety-net hospitals